Analysis of semaglutide's effect on Alzheimer's disease risk.
作者信息
Hsu Chi-Kuei, Lai Chih-Cheng
机构信息
Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
School of Medicine for International Students, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
出版信息
Alzheimers Dement. 2025 Feb;21(2):e14462. doi: 10.1002/alz.14462. Epub 2024 Dec 31.
Abstract
摘要
相似文献
1
Analysis of semaglutide's effect on Alzheimer's disease risk.
Alzheimers Dement. 2025 Feb;21(2):e14462. doi: 10.1002/alz.14462. Epub 2024 Dec 31.
2
Response to the letter titled "Analysis of semaglutide's effect on Alzheimer's disease risk".对题为“司美格鲁肽对阿尔茨海默病风险的影响分析”的信件的回复。
Alzheimers Dement. 2025 Feb;21(2):e14509. doi: 10.1002/alz.14509. Epub 2025 Jan 14.
3
Oral Formulation and SGLT2i Interaction: Key Nuances in Semaglutide's Effect on Atrial Fibrillation.
Eur J Prev Cardiol. 2025 May 6. doi: 10.1093/eurjpc/zwaf280.
4
Unlocking the Potential: Semaglutide's Impact on Alzheimer's and Parkinson's Disease in Animal Models.释放潜力：司美格鲁肽在动物模型中对阿尔茨海默病和帕金森病的影响
Curr Issues Mol Biol. 2024 Jun 13;46(6):5929-5949. doi: 10.3390/cimb46060354.
5
Clarifying the interpretation of semaglutide's impact in the FLOW study.
Kidney Int. 2025 May;107(5):939-940. doi: 10.1016/j.kint.2025.01.028.
6
Semaglutide's Weight-Loss Benefits Were Sustained in a 2-Year Study.司美格鲁肽的减肥益处在一项为期两年的研究中得以维持。
JAMA. 2021 Dec 28;326(24):2464. doi: 10.1001/jama.2021.21717.
7
Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US.司美格鲁肽与2型糖尿病患者首次诊断阿尔茨海默病的关联：利用美国全国性真实世界数据进行目标试验模拟
Alzheimers Dement. 2024 Dec;20(12):8661-8672. doi: 10.1002/alz.14313. Epub 2024 Oct 24.
8
As Semaglutide's Popularity Soars, Rare but Serious Adverse Effects Are Emerging.随着司美格鲁肽的人气飙升，罕见但严重的不良反应正在出现。
JAMA. 2023 Dec 12;330(22):2140-2142. doi: 10.1001/jama.2023.16620.
9
Semaglutide's Success Could Usher in a "New Dawn" for Obesity Treatment.司美格鲁肽的成功可能为肥胖症治疗带来“新曙光”。
JAMA. 2021 Jul 13;326(2):121-123. doi: 10.1001/jama.2021.10307.
10
Semaglutide's CVD indication could cost US Medicare $145bn extra a year.司美格鲁肽的心血管疾病适应症可能使美国医疗保险每年额外花费1450亿美元。
BMJ. 2024 Aug 28;386:q1878. doi: 10.1136/bmj.q1878.
引用本文的文献
1
Targeting dementia prevention with semaglutide: The case for APOE4 homozygotes.用司美格鲁肽预防痴呆症：载脂蛋白E4纯合子的情况
Alzheimers Dement. 2025 Jun;21(6):e70422. doi: 10.1002/alz.70422.
本文引用的文献
1
Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US.司美格鲁肽与2型糖尿病患者首次诊断阿尔茨海默病的关联：利用美国全国性真实世界数据进行目标试验模拟
Alzheimers Dement. 2024 Dec;20(12):8661-8672. doi: 10.1002/alz.14313. Epub 2024 Oct 24.
2
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission.《痴呆症的预防、干预与照护：柳叶刀委员会2020年报告》
Lancet. 2020 Aug 8;396(10248):413-446. doi: 10.1016/S0140-6736(20)30367-6. Epub 2020 Jul 30.
3
Prevention of dementia by targeting risk factors.通过针对风险因素预防痴呆症。
Lancet. 2018 Apr 21;391(10130):1574-1575. doi: 10.1016/S0140-6736(18)30578-6.
4
Contribution of alcohol use disorders to the burden of dementia in France 2008-13: a nationwide retrospective cohort study.2008-2013 年法国因酒精使用障碍导致的痴呆负担：一项全国性回顾性队列研究。
Lancet Public Health. 2018 Mar;3(3):e124-e132. doi: 10.1016/S2468-2667(18)30022-7. Epub 2018 Feb 21.
5
Multimorbidity and Risk of Mild Cognitive Impairment.多种疾病并存与轻度认知障碍风险
J Am Geriatr Soc. 2015 Sep;63(9):1783-90. doi: 10.1111/jgs.13612. Epub 2015 Aug 27.
6
Social relationships and risk of dementia: A systematic review and meta-analysis of longitudinal cohort studies.社会关系与痴呆风险：一项基于纵向队列研究的系统回顾和荟萃分析。
Ageing Res Rev. 2015 Jul;22:39-57. doi: 10.1016/j.arr.2015.04.006. Epub 2015 May 5.
Zotero 插件